This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Brain Stimulation12:119-128(2018)
Authors: S Senova, G Cotovio, A Pascual-leone, A.J OlivieraMaia
The therapeutic options for treatment-resistant depression (TRD) encompass a range of neuromodulatorytechniques, including repetitive transcranial magnetic stimulation (rTMS). While rTMS is safe and has documented short-term efficacy, durability of antidepressant effects is poorly established.
Assess existing evidence regarding durability of rTMS-induced antidepressant response.
The authors performed a systematic review of studies reporting antidepressant outcome measures collected three or more months after the end of an induction course of rTMS for depression. Among responders to the induction course, we used a meta-analytic approach to assess response rates at 3 (m3), 6 (m6) or 12 (12m)months after induction and studied predictors of responder rates using meta-regression.
Nineteen studies published between 2002 and 2018 were included. Eighteen were eligible for analysis at m3 (732 patients) and m6 (695 patients) and nine at m12 (247 patients). Among initial responders, 66.5% sustained response at m3 (95% CI=57.1-74.8%, I 2 =27.6%), 52.9% at m6 (95% CI=40.3-65%, I2 =0%), and 46.3% at m12 (95% CI=32.6-60.7%, I2 =0%), in the absenceof any major bias. Random-effects meta-regressions further demonstrated that a higher proportion of women, as well as receipt of maintenance treatment, predicted higher responder rates at specific time-points.
rTMS is a durable treatment for depression, with sustained responder rates of 50% up to 1 year after a successful induction course of treatment. Maintenance treatment may enhance the durability of the antidepressant effects of rTMS, and should be considered in clinical practice, as well as systematically explored in future clinical trials.